FDA Says Popular ‘Weight Loss Meds’ No Longer in Shortage: What Patients Need to Know
12/20/24 • 79 min
Resources for the Community:
___________________________________________________________________
Ro - Telehealth for GLP1 weight management
https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55https://a4pc.org/find-a-compounder/
If You are having issues accessing Paid Subscriber content please send an email to [email protected] and a member of Buzzsprout's technical team will help you access the content.
_____________________________________________________________________
In this timely bonus episode of The Plus SideZ Podcast, we dive into the FDA’s decision to end the tirzepatide shortage, its 60-90 day grace period for compounding pharmacies, and what this means for patients relying on affordable access to GLP-1 medications like Zepbound and Mounjaro. Joining us is Scott Brunner, CEO of the Alliance for Pharmacy Compounding, to discuss the impact of this ruling, safety concerns, and the role of compounded medications in obesity care.
We also explore the new PBM reform bill, aiming to address access and affordability challenges for patients. Whether you’re a patient, provider, or advocate, this episode unpacks the critical issues shaping the future of obesity and diabetes treatments.
Tune in to learn how to navigate these changes and make informed decisions for your health. #GLP1 #Tirzepatide #ObesityCare #PBMReform
______________________________________________________________________
⭐️Mounjaro Stanley⭐️
griffintumblerco.Etsy.com
Use code PODCAST10 for $ OFF
______________________________________________________________________
Join this channel to get access to perks:
/ @theplussidez______________________________________________________________________
#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide #GLP1 #Obesity #zepbound #wegovy
Kim Carlos, Executive Producer
TikTok
https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc
https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr
Kat Carter, Associate Producer
TikTok
https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc
https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==
Resources for the Community:
___________________________________________________________________
Ro - Telehealth for GLP1 weight management
https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55https://a4pc.org/find-a-compounder/
If You are having issues accessing Paid Subscriber content please send an email to [email protected] and a member of Buzzsprout's technical team will help you access the content.
_____________________________________________________________________
In this timely bonus episode of The Plus SideZ Podcast, we dive into the FDA’s decision to end the tirzepatide shortage, its 60-90 day grace period for compounding pharmacies, and what this means for patients relying on affordable access to GLP-1 medications like Zepbound and Mounjaro. Joining us is Scott Brunner, CEO of the Alliance for Pharmacy Compounding, to discuss the impact of this ruling, safety concerns, and the role of compounded medications in obesity care.
We also explore the new PBM reform bill, aiming to address access and affordability challenges for patients. Whether you’re a patient, provider, or advocate, this episode unpacks the critical issues shaping the future of obesity and diabetes treatments.
Tune in to learn how to navigate these changes and make informed decisions for your health. #GLP1 #Tirzepatide #ObesityCare #PBMReform
______________________________________________________________________
⭐️Mounjaro Stanley⭐️
griffintumblerco.Etsy.com
Use code PODCAST10 for $ OFF
______________________________________________________________________
Join this channel to get access to perks:
/ @theplussidez______________________________________________________________________
#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide #GLP1 #Obesity #zepbound #wegovy
Kim Carlos, Executive Producer
TikTok
https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc
https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr
Kat Carter, Associate Producer
TikTok
https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc
https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==
Previous Episode
Semaglutide vs. Tirzepitide: Which Obesity Drug Could Be Your Game Changer Part 1
Resources for the Community:
____________________________________________________________________________________________
https://linktr.ee/theplussidezpodcast
Ro - Telehealth for GLP1 weight management
https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55If You are having issues accessing Paid Subscriber content please send an email to [email protected] and a member of Buzzsprout's technical team will help you access the content.
____________________________________________________________________________________________
Part 1
This episode delves into the intricate relationship between insulin resistance, polycystic ovarian syndrome (PCOS), and obesity. We explore how these conditions often intertwine, leading to a cyclical pattern that can be challenging to break.
We discuss the fascinating study of adipose tissue's remarkable ability to remember past weight gain, even after significant weight loss. This phenomenon sheds light on the persistent challenges faced by individuals who have lost weight and are striving to maintain their progress.
We also delve into the critical role of basal metabolic rate (BMR) and caloric consumption in weight management. Understanding these factors can empower individuals to make informed choices about their diet and exercise routines.
Finally, we compare and contrast two groundbreaking medications, semaglutide and tirzepitide. Both drugs have shown remarkable efficacy in treating obesity, but there are key differences in their mechanisms of action and potential side effects. We explore the latest research to determine which medication may be the best fit for different individuals.
____________________________________________________________________________________________
⭐️Mounjaro Stanley⭐️
griffintumblerco.Etsy.com
Use code PODCAST10 for $ OFF
____________________________________________________________________________________________
Join this channel to get access to perks:
/ @theplussidez______________________________________________________________________
#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide #GLP1 #Obesity #zepbound #wegovy
Kim Carlos, Executive Producer
TikTok
https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc
https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr
Kat Carter, Associate Producer
TikTok
https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc
https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==
Next Episode
Semaglutide vs. Tirzepitide: Which Obesity Drug Could Be Your Game Changer Part 2
Resources for the Community:
____________________________________________________________________________________________
https://linktr.ee/theplussidezpodcast
Ro - Telehealth for GLP1 weight management
https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55If You are having issues accessing Paid Subscriber content please send an email to [email protected] and a member of Buzzsprout's technical team will help you access the content.
____________________________________________________________________________________________
Part 2
This episode delves into the intricate relationship between insulin resistance, polycystic ovarian syndrome (PCOS), and obesity. We explore how these conditions often intertwine, leading to a cyclical pattern that can be challenging to break.
We discuss the fascinating study of adipose tissue's remarkable ability to remember past weight gain, even after significant weight loss. This phenomenon sheds light on the persistent challenges faced by individuals who have lost weight and are striving to maintain their progress.
We also delve into the critical role of basal metabolic rate (BMR) and caloric consumption in weight management. Understanding these factors can empower individuals to make informed choices about their diet and exercise routines.
Finally, we compare and contrast two groundbreaking medications, semaglutide and tirzepitide. Both drugs have shown remarkable efficacy in treating obesity, but there are key differences in their mechanisms of action and potential side effects. We explore the latest research to determine which medication may be the best fit for different individuals.
____________________________________________________________________________________________
⭐️Mounjaro Stanley⭐️
griffintumblerco.Etsy.com
Use code PODCAST10 for $ OFF
____________________________________________________________________________________________
Join this channel to get access to perks:
/ @theplussidez______________________________________________________________________
#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide #GLP1 #Obesity #zepbound #wegovy
Kim Carlos, Executive Producer
TikTok
https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc
https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr
Kat Carter, Associate Producer
TikTok
https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc
https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/the-plus-sidez-cracking-the-obesity-code-360464/fda-says-popular-weight-loss-meds-no-longer-in-shortage-what-patients-80447789"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to fda says popular ‘weight loss meds’ no longer in shortage: what patients need to know on goodpods" style="width: 225px" /> </a>
Copy